<DOC>
	<DOCNO>NCT02806791</DOCNO>
	<brief_summary>The endogenous growth factor granulocyte ( G-CSF ) stimulate proliferation differentiation hematopoietic progenitor commission mature neutrophil activate granulocyte mature neutrophil . In field hematology oncology G-CSF use reduce duration complication chemotherapy-induced neutropenia stimulate mobilization subsequent collection circulate hematopoietic stem cell order use autologous transplantation procedure . Filgrastim Lenograstim originator market many year consider reference molecule production biosimilar . For several year available enter common clinical practice use filgrastim biosimilar ( Bio-GCSF ) treat patient oncohematologic . Aim study analyze retrospectively large series patient assess impact Bio-GCSF collection hematopoietic stem cell recovery blood count post autologous transplantation ; data compare historical cohort reference treat G-CSF originator . The study result generate diagnostic therapeutic intervention patient still alive .</brief_summary>
	<brief_title>Efficacy Biosimilar Filgrastim Mobilization Hematopoietic Stem Cell CD34+ ( Cluster Differentiation 34 ) Kinetic Engraftment</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>&gt; 18 year history autologous transplant hematological disease include : Multiple Myeloma Hodgkin 's Lymphoma NonHodgkin lymphoma B T Lymphocytic leukemia Acute myeloid leukemia N.A .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Patients</keyword>
</DOC>